Christopher D. Herzog, Ph.D. - Publications


32 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.


Year Citation  Score
2015 Warren Olanow C, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, Turner DA, Marks W, Larson P, Starr PA, Jankovic J, Simpson R, Watts R, Guthrie B, Poston K, ... ... Herzog C, et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Annals of Neurology. 78: 248-57. PMID 26061140 DOI: 10.1002/ana.24436  0.68
2015 Bartus RT, Kordower JH, Johnson EM, Brown L, Kruegel BR, Chu Y, Baumann TL, Lang AE, Olanow CW, Herzog CD. Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies. Neurobiology of Disease. 78: 162-71. PMID 25841760 DOI: 10.1016/j.nbd.2015.03.023  0.68
2014 Rafii MS, Baumann TL, Bakay RA, Ostrove JM, Siffert J, Fleisher AS, Herzog CD, Barba D, Pay M, Salmon DP, Chu Y, Kordower JH, Bishop K, Keator D, Potkin S, et al. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: 571-81. PMID 24411134 DOI: 10.1016/j.jalz.2013.09.004  0.68
2013 Herzog CD, Brown L, Kruegel BR, Wilson A, Tansey MG, Gage FH, Johnson EM, Bartus RT. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120). Neurobiology of Disease. 58: 38-48. PMID 23631873 DOI: 10.1016/j.nbd.2013.04.011  0.68
2013 Bartus RT, Baumann TL, Siffert J, Herzog CD, Alterman R, Boulis N, Turner DA, Stacy M, Lang AE, Lozano AM, Olanow CW. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology. 80: 1698-701. PMID 23576625 DOI: 10.1212/WNL.0b013e3182904faa  0.68
2013 Bartus RT, Baumann TL, Brown L, Kruegel BR, Ostrove JM, Herzog CD. Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease. Neurobiology of Aging. 34: 35-61. PMID 22926166 DOI: 10.1016/j.neurobiolaging.2012.07.018  0.68
2011 Herzog CD, Bishop KM, Brown L, Wilson A, Kordower JH, Bartus RT. Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases. Drug Delivery and Translational Research. 1: 361-82. PMID 25788422 DOI: 10.1007/s13346-011-0037-z  0.68
2011 Bartus RT, Brown L, Wilson A, Kruegel B, Siffert J, Johnson EM, Kordower JH, Herzog CD. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiology of Disease. 44: 38-52. PMID 21704161 DOI: 10.1016/j.nbd.2011.05.026  0.68
2011 Bartus RT, Herzog CD, Chu Y, Wilson A, Brown L, Siffert J, Johnson EM, Olanow CW, Mufson EJ, Kordower JH. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 27-36. PMID 21322017 DOI: 10.1002/mds.23442  0.68
2009 Herzog CD, Brown L, Gammon D, Kruegel B, Lin R, Wilson A, Bolton A, Printz M, Gasmi M, Bishop KM, Kordower JH, Bartus RT. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery. 64: 602-12; discussion 6. PMID 19349823 DOI: 10.1227/01.NEU.0000340682.06068.01  0.68
2009 Ramaswamy S, McBride JL, Han I, Berry-Kravis EM, Zhou L, Herzog CD, Gasmi M, Bartus RT, Kordower JH. Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiology of Disease. 34: 40-50. PMID 19150499 DOI: 10.1016/j.nbd.2008.12.005  0.68
2008 Herzog CD, Dass B, Gasmi M, Bakay R, Stansell JE, Tuszynski M, Bankiewicz K, Chen EY, Chu Y, Bishop K, Kordower JH, Bartus RT. Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1737-44. PMID 18728639 DOI: 10.1038/mt.2008.170  0.68
2007 Bartus RT, Herzog CD, Bishop K, Ostrove JM, Tuszynski M, Kordower JH, Gasmi M. Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point. Parkinsonism & Related Disorders. 13: S469-77. PMID 18267286 DOI: 10.1016/S1353-8020(08)70052-X  0.68
2007 Gasmi M, Brandon EP, Herzog CD, Wilson A, Bishop KM, Hofer EK, Cunningham JJ, Printz MA, Kordower JH, Bartus RT. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiology of Disease. 27: 67-76. PMID 17532642 DOI: 10.1016/j.nbd.2007.04.003  0.68
2007 Herzog CD, Dass B, Holden JE, Stansell J, Gasmi M, Tuszynski MH, Bartus RT, Kordower JH. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 1124-32. PMID 17443702 DOI: 10.1002/mds.21503  0.68
2007 Ramaswamy S, McBride JL, Herzog CD, Brandon E, Gasmi M, Bartus RT, Kordower JH. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease. Neurobiology of Disease. 26: 375-84. PMID 17336076 DOI: 10.1016/j.nbd.2007.01.003  0.68
2007 Gasmi M, Herzog CD, Brandon EP, Cunningham JJ, Ramirez GA, Ketchum ET, Bartus RT. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 62-8. PMID 17164776 DOI: 10.1038/  0.68
2006 Kordower JH, Herzog CD, Dass B, Bakay RA, Stansell J, Gasmi M, Bartus RT. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Annals of Neurology. 60: 706-15. PMID 17192932 DOI: 10.1002/ana.21032  0.68
2006 McBride JL, Ramaswamy S, Gasmi M, Bartus RT, Herzog CD, Brandon EP, Zhou L, Pitzer MR, Berry-Kravis EM, Kordower JH. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 103: 9345-50. PMID 16751280 DOI: 10.1073/pnas.0508875103  0.68
2003 Herzog CD, Nowak KA, Sarter M, Bruno JP. Microdialysis without acetylcholinesterase inhibition reveals an age-related attenuation in stimulated cortical acetylcholine release. Neurobiology of Aging. 24: 861-3. PMID 12927768 DOI: 10.1016/S0197-4580(02)00226-9  0.68
2002 Herzog CD, Otto T. Administration of transforming growth factor-alpha enhances anatomical and behavioral recovery following olfactory nerve transection. Neuroscience. 113: 569-80. PMID 12150777 DOI: 10.1016/S0306-4522(02)00203-8  0.68
2002 Burk JA, Herzog CD, Porter MC, Sarter M. Interactions between aging and cortical cholinergic deafferentation on attention. Neurobiology of Aging. 23: 467-77. PMID 11959409 DOI: 10.1016/S0197-4580(01)00315-3  0.68
2000 Otto T, Cousens G, Herzog C. Behavioral and neuropsychological foundations of olfactory fear conditioning. Behavioural Brain Research. 110: 119-28. PMID 10802309 DOI: 10.1016/S0166-4328(99)00190-4  0.68
2000 Herzog CD, Gandhi C, Bhattacharya P, Walsh TJ. Effects of intraseptal zolpidem and chlordiazepoxide on spatial working memory and high-affinity choline uptake in the hippocampus. Neurobiology of Learning and Memory. 73: 168-79. PMID 10704326 DOI: 10.1006/nlme.1999.3928  0.68
1999 Herzog C, Otto T. Regeneration of olfactory receptor neurons following chemical lesion: time course and enhancement with growth factor administration. Brain Research. 849: 155-61. PMID 10592297 DOI: 10.1016/S0006-8993(99)02075-2  0.68
1998 Herzog C, Otto T. Contributions of anterior perirhinal cortex to olfactory and contextual fear conditioning. Neuroreport. 9: 1855-9. PMID 9665615  0.68
1997 Herzog C, Otto T. Odor-guided fear conditioning in rats: 2. Lesions of the anterior perirhinal cortex disrupt fear conditioned to the explicit conditioned stimulus but not to the training context. Behavioral Neuroscience. 111: 1265-72. PMID 9438795 DOI: 10.1037/0735-7044.111.6.1265  0.68
1996 Herzog CD, Stackman RW, Walsh TJ. Intraseptal flumazenil enhances, while diazepam binding inhibitor impairs, performance in a working memory task. Neurobiology of Learning and Memory. 66: 341-52. PMID 8946426 DOI: 10.1006/nlme.1996.0074  0.68
1996 Walsh TJ, Herzog CD, Gandhi C, Stackman RW, Wiley RG. Injection of IgG 192-saporin into the medial septum produces cholinergic hypofunction and dose-dependent working memory deficits. Brain Research. 726: 69-79. PMID 8836547 DOI: 10.1016/S0006-8993(96)00271-5  0.68
1992 Bowers RL, Herzog CD, Stone EH, Dionne TJ. Defensive burying following injections of cholecystokinin, bombesin, and LiCl in rats. Physiology & Behavior. 51: 969-72. PMID 1319591 DOI: 10.1016/0031-9384(92)90079-H  0.68
1991 Bowers RL, Herzog CD. Bombesin effects on responding maintained by a fixed interval schedule of food reinforcement. Peptides. 12: 1435-6. PMID 1815229 DOI: 10.1016/0196-9781(91)90229-I  0.68
1986 Block LH, Georgopoulos A, Biemesderfer D, Herzog C, Kashgarian M, Sitaramam V. Ubiquinone-8 stimulates phagocytosis in macrophages by modulation of the kinetics of the Fc receptor Journal of Infectious Diseases. 153: 209-216. PMID 3944478  0.68
Show low-probability matches.